A press release on the headline results of the Alemtuzumab vs. Interferon-beta-1a trial:
"Sanofi said Lemtrada worked better than an older drug, Rebif, in preventing relapses, as patients treated with Lemtrada were 55 percent less likely to experience a relapse in symptoms. However, the drug did not prevent their multiple sclerosis from becoming disabling, as it had in previous studies."
"I was expecting better; it shows you that phase 2 studies don't always translate into phase 3 results. I suspect this occurred because the MS'ers in the current or phase 3 study, were not as active as those in the phase 2 study. Are you disappointed?"
Data source: Forbes press release